• Philips reported Q3 2026 income from operations of EUR 165 million and sales of EUR 4.4 billion.
• Operating cash flow rose to EUR 544 million, while free cash flow increased to EUR 384 million.
• Respironics reached an agreement in principle with the US Department of Justice over recall investigations; Philips recorded a EUR 288 million provision.
• The group reiterated its full-year 2026 outlook, including free cash flow of EUR 1.5–1.7 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royal Philips NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030100PRIMZONEFULLFEED1001301420) on November 03, 2026, and is solely responsible for the information contained therein.